Waycross Partners LLC Increases Position in IDEXX Laboratories, Inc. $IDXX

Waycross Partners LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% during the 3rd quarter, Holdings Channel reports. The firm owned 43,471 shares of the company’s stock after acquiring an additional 961 shares during the period. IDEXX Laboratories comprises 2.4% of Waycross Partners LLC’s investment portfolio, making the stock its 18th biggest position. Waycross Partners LLC’s holdings in IDEXX Laboratories were worth $27,773,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of IDXX. WealthCollab LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $30,000. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the third quarter worth $31,000. Armstrong Advisory Group Inc. boosted its position in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in IDEXX Laboratories during the third quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $35,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

IDXX stock opened at $626.17 on Wednesday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The firm has a market cap of $50.00 billion, a price-to-earnings ratio of 47.91, a PEG ratio of 3.83 and a beta of 1.67. The business’s fifty day simple moving average is $681.98 and its two-hundred day simple moving average is $669.66. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the business earned $2.53 EPS. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

IDXX has been the subject of a number of research analyst reports. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Piper Sandler reduced their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.